ABIONYX Pharma SA (0RAG.L)
| Previous close | 2.0485 |
| Open | 1.9114 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.9114 - 1.9460 |
| 52-week range | 1.9114 - 1.9460 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 429,060 |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ABIONYX Pharma: Press Release
TOULOUSE, France & LAKELAND, Mich., February 03, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today that it has been informed by TVM Capital of the total sale of their shares on the market due to the liquidation of their funds that have reached maturity.
- Business Wire
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
TOULOUSE, France & LAKELAND, Mich., January 16, 2023--ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the pilot Phase 2a clinical trial evaluating CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI) met its primary objective. There are no approved treatments for septic patie
- Business Wire
ABIONYX Pharma Announces Its Financial Agenda for the Year 2023
TOULOUSE, France & LAKELAND, Mich., January 13, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2023.
